Icatibant Acetate API

Name	Icatibant acetate
Chinese name	醋酸艾替班特
Cas Number	138614-30-9
Source	Japan
Qualifications	USDMF/-/-/-/-

Developed by Shire, it was approved to be marketed in the United States in 2011, and the drug was granted orphan drug status. Iatibant (Firazyr) is a bradykinin receptor antagonist. Studies have shown that it can effectively treat ACE inhibitor-related angioedema. It is the third approved in the United States for the treatment of HAE attacks drug. The Pharmaceutical Comprehensive Database (PDB) shows that the icatibant market continues to grow in the global market, with a compound growth rate of more than 30%. In 2018, the market sales were 410 million US dollars. In 2019, the China National Health and Construction Commission included icatibant in the "First Batch of Catalogues of Encouraging Generic Drugs."

Hot Tags: icatibant acetate api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Pleasant API, Adapalene API, Bemeprost API, Pazopanib Hydrochloride Pazopanib API, Itraconazole Hydrochloride API, Tippyridine Hydrochloride API

• Previous: Dutasteride API
• Next: Tolvaptan API